[{"address1": "155 Bovet Road", "address2": "Suite 303", "city": "San Mateo", "state": "CA", "zip": "94402", "country": "United States", "phone": "650-561-8600", "website": "https://sagimet.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. George W. Kemble Ph.D.", "age": 62, "title": "Executive Chairman of the Board", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 444856, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David A. Happel", "age": 61, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 309417, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 536833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Urs  Greber Ph.D.", "title": "Co-Founder", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lucas  Pelkmans Ph.D.", "title": "Co-Founder", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony M. Rimac CPA, CPA", "age": 59, "title": "CFO & Principal Accounting Officer", "yearBorn": 1964, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Rozek J.D.", "age": 52, "title": "General Counsel & Chief Compliance Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marie  O'Farrell Ph.D.", "title": "Senior Vice President of Research & Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 16.23, "open": 15.89, "dayLow": 13.82, "dayHigh": 16.68, "regularMarketPreviousClose": 16.23, "regularMarketOpen": 15.89, "regularMarketDayLow": 13.82, "regularMarketDayHigh": 16.68, "forwardPE": -6.5514016, "volume": 1079499, "regularMarketVolume": 1079499, "averageVolume": 800773, "averageVolume10days": 4145330, "averageDailyVolume10Day": 4145330, "bidSize": 1000, "askSize": 3100, "marketCap": 321000544, "fiftyTwoWeekLow": 2.13, "fiftyTwoWeekHigh": 20.71, "priceToSalesTrailing12Months": 160.50027, "fiftyDayAverage": 5.5193, "twoHundredDayAverage": 8.5995865, "currency": "USD", "enterpriseValue": 219261408, "floatShares": 10488379, "sharesOutstanding": 21375400, "sharesShort": 621997, "sharesShortPriorMonth": 470420, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0272, "heldPercentInsiders": 0.19097, "heldPercentInstitutions": 0.71948, "shortRatio": 4.03, "shortPercentOfFloat": 0.0394, "impliedSharesOutstanding": 22895900, "bookValue": 4.275, "priceToBook": 3.2795322, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -26920000, "trailingEps": -1.18, "forwardEps": -2.14, "enterpriseToRevenue": 109.631, "52WeekChange": 0.01755488, "SandP52WeekChange": 0.20233083, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SGMT", "underlyingSymbol": "SGMT", "shortName": "Sagimet Biosciences Inc. - Seri", "longName": "Sagimet Biosciences Inc.", "firstTradeDateEpochUtc": 1689600600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "036364bd-80e6-3704-a7f9-b8281c4b4a2f", "messageBoardId": "finmb_34541828", "gmtOffSetMilliseconds": -18000000, "currentPrice": 14.02, "targetHighPrice": 67.0, "targetLowPrice": 37.0, "targetMeanPrice": 50.33, "targetMedianPrice": 47.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 101842000, "totalCashPerShare": 4.448, "totalDebt": 103000, "quickRatio": 20.171, "currentRatio": 20.364, "totalRevenue": 2000000, "debtToEquity": 0.105, "revenuePerShare": 0.431, "operatingCashflow": -24136000, "grossMargins": 1.0, "operatingMargins": -3.726, "financialCurrency": "USD", "trailingPegRatio": null}]